Dantrolene sodium (DrugBank: Dantrolene)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 233 | Wolfram syndrome | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02829268 (ClinicalTrials.gov) | January 2017 | 6/7/2016 | A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome | A Phase 1b/2a Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome | Wolfram Syndrome;Diabetes Mellitus;Optic Nerve Atrophy;Ataxia | Drug: dantrolene sodium | Washington University School of Medicine | National Institutes of Health (NIH);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting | 5 Years | 60 Years | All | 50 | Phase 1;Phase 2 | United States |